CS Paper Radar

Does Your Trial Simulator Know What the Drug Does? An Intervention-Blind Test of Interventional Validity on 7,207 Registered Trials

Alicem Koyun

cs.AI stat.APcs.LG ·submitted 2026-11-04 03:59 UTC · v1
publishedbenchmarktheorycode/data

Abstract

Patient world models are increasingly proposed as simulators of clinical trials, and recent surveys rank their capabilities on a ladder from temporal prediction to counterfactual rollouts. Position on that ladder is currently assigned by reading papers rather than by measurement. We turn the counterfactual rung into a measured quantity. From 30,119 completed phase 2/3 trials with results posted to ClinicalTrials.gov we construct 9,996 audited within-trial contrasts from 7,207 trials, and we score a simulator on how much of its accuracy depends on knowing which intervention was tested. The instrument is an intervention-blind reference: the same model, trained on the same trials, with every intervention-identifying field withheld. Interventional skill is the error the full model removes relative to that reference. On a temporal split (878 test contrasts from 655 trials) a registry-trained gradient-boosting simulator removes a fifth of the error of a trivial baseline, but its interventional skill is -0.12 (95% CI -0.21 to -0.05): withholding the intervention makes it better, and no alternative featurisation, stratum, temporal cut or same-molecule retrieval yields an interval above zero. A frontier language model reading only the registered protocol has interventional skill 0.20 [0.08, 0.31]; smaller and open-weight models sit at the limit of detection. Perturbation tests show the large model uses the intervention as such: swapping the arms reverses the sign of its prediction in 86% of contrasts. The blind reference is itself not drug-blind (a language model recovers the withheld drug class 45% of the time from the blind prompt), so interventional skill is a conservative lower bound. A reliability layer shows that ranking by predicted error lowers it but that calibrated error control does not transfer under temporal shift. Benchmark, code, prompts and per-call model outputs are released.

Comment
Oral presentation at the NeurIPS 2026 Workshop on World Models for High-Stakes Health. 31 pages, 5 figures. Code and data: https://github.com/alicemkyn/ivbench

Closest papers

Nearest neighbours by meaning across the whole index.

Where Does Hindsight Enter Clinical Agent Benchmarks? An Audit of Simulators and Case Construction

cs.CL ·2026-11-17 ·Meilu Zhu, Xiaohan Li, Axiu Mao
benchmarktheory similarity 0.61
Abstract · 8 pages main text, 20 pages in total, 6 figures, 11 tables

Benchmarks for LLM diagnostic agents are built from retrospective records: the case an agent reads is rewritten from discharge summaries, and unrecorded test results are generated by a simulator that often sees the final diagnosis. HindAudit separates three hindsight channels (the diagnosis given to the simulator, the retrospective context it conditions on, and the agent-facing case text) and measures each with judges trained only on real data. On 27,489 emergency admissions from MIMIC-IV, five registered tests found no leakage into simulated laboratory results: providing the diagnosis to five simulators had a negligible effect, and prompted gatekeepers diluted the diagnostic signal, although exploratory results suggest they can raise agent scores. The largest effect lay in the case text. Against a presentation-time reconstruction from triage records, benchmark-style summaries raised the zero-shot accuracy of four LLMs from 25.4% to 39.7% and discharge histories to 45.3%, and raised six interactive agents' scores while barely changing their ranking. The exploratory gap was reproduced in a registered replication on held-out patients. Masking diagnosis names left it unchanged. Because MIMIC lacks a contemporaneous bedside history, the gap is an upper bound on hindsight. We report all registered outcomes and recommend construction practices.

0.33

Auditing black-box clinical prediction models with a large language model through queries alone: a blinded test with planted flaws

cs.LG cs.AI ·2026-11-18 ·Zhiyu Liu, Xinyu Yang
code/data similarity 0.61
Abstract · 15 pages, 2 figures, 6 tables. Models, prompts, replies with tool calls, and code: https://github.com/Chth1z/llm-black-box-model-audit

Large language models (LLMs) are used to explain clinical prediction models, on the promise that they can say what a model computes, find its faults and even reveal new knowledge in it. We tested the three promises where the answers could be checked. From the International Stroke Trial we trained four kinds of model (logistic regression, explainable boosting machine, gradient-boosted trees, neural network) for two outcomes on patients randomised earlier, planted one flaw in each of 24 copies (an under-predicted subgroup, a reversed risk factor or an implausible step) and mixed them with the 8 clean models. GPT-6 Astra audited each model three times, blind, through a tool that only returned the model's predictions; the judging rules were committed before any run and applied by program. Its surrogate models, with a median of 128 terms, reproduced the audited models' log-odds with a mean $R^2$ of 0.976 (0.959 for an additive surrogate of 42 terms fitted by an analyst). It found the planted flaw in 69 of 72 runs (96%; 95% CI 80% to 99%); a script written for the purpose found all 24. It also reported many more problems: 60% of 1,089 checkable reports failed the pre-specified check against the model's average behaviour; post hoc, most of these were real but small steps, and 15% of the checkable reports were not found in the model. Of 601 unexpected relationships it read out of the clean models, 11% held in patients randomised later (random pairs 6%; a regression scan's shorter list of its strongest candidates, 28%); after a check on the training data, 33% against 30%. With query access alone, an LLM can describe a black-box model faithfully and find nearly every planted flaw, as a purpose-written script also did; its reports of problems must be checked on the model and its discoveries on data.

0.24

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

cs.LG ·2026-11-06 ·Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains
code/data similarity 0.59
Abstract · 38 pages. Code: https://github.com/oibrahi1/TrialJev. Models: https://huggingface.co/omareng/TrialJev

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

0.22

Intervention Granularity Matters: Coherent Treatment Bundles in Counterfactual Simulation with Clinical World Models

cs.LG ·2026-09-18 ·Fangzhou Wang, Yixuan Yang, Camilla Balzarotti, Rishikesan Kamaleswaran
similarity 0.58
Abstract

Counterfactual simulation with a clinical world model means fixing a patient's history, changing the treatment, and reading off the predicted response. Doing so requires deciding what counts as one intervention. In clinical settings, interventions are documented as bundles: a co-occurrence audit of 945,707 patient-hours from MIMIC-IV shows groups of components, such as every parameter of a dialysis circuit, that never appear apart, so an edit that changes one component on its own describes an hour that never occurs in the data. We hypothesize that the granularity at which an intervention is edited changes how a world model responds, and test this with Clin-JEPA, a latent world model of patient trajectories conditioned on hourly treatment text. At 1,019 documented onsets of invasive ventilation, we keep the patient's history and other treatments fixed and compare editing one ventilator setting with editing the complete configuration recorded for a real patient with the most similar recent trajectory. The complete bundle moves the predicted next state further than any single setting, consistently across all five settings, and the difference remains after accounting for how much each edit changes the model's input. Intervention granularity therefore materially affects the response of a clinical world model: single-component edits may understate treatment sensitivity, and bundle-aware editing may offer a better-supported basis for counterfactual treatment simulation.

0.31

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.57
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.45

One Verdict Is Not Enough: Regression Testing Learned World Models and Their Test Harnesses

cs.SE cs.AIcs.CV ·2026-10-30 ·Junyu Huo, Zihao Wan, Ziqi Mao, Gouri Ginde
similarity 0.56
Abstract

Learned world models ship as software components whose model versions, preprocessing, and test harnesses change between releases. Work on model updates already counts per-sample regressions, or negative flips, that an accuracy check hides. Two problems remain: a test can pass under one configuration and fail under another, and a harness fault can produce erroneous scores and wrong verdicts without a crash. We present TetraState, a regression-testing protocol for paired possible/impossible video tests. Each test runs under four fixed model-native configurations; its number of correct verdicts assigns one of four outcome classes. Inconclusive tests and failed executions are reported separately alongside the verdict rate. Revisions are compared by per-test outcome transitions, and the harness is versioned as part of the system under test. On all 506 IntPhys 2 Main tests and two heterogeneous systems, Cosmos 3 Nano and V-JEPA 2, two V-JEPA 2 harness revisions move modal accuracy by only 0.2 and 2.6 points yet change 11 and 214 test labels; in the second, accuracy rises although fewer tests are judged correctly, and 43 regressions keep the modal verdict, so a modal-verdict flip check misses them. These results outline a research agenda on configuration-level regression oracles for learned components.

0.14

Agent Verifiers in Counterfactual Analysis: A Pilot Study Benchmarking Agentic Heterogeneous Treatment Effects

cs.LG ·2026-11-17 ·Satiyabooshan Murugaboopathy, Entejar Alam, Adel Daoud, Connor T. Jerzak
publishedbenchmark similarity 0.56
Abstract · NeurIPS 2026 Workshop: Who Verifies the Agents? Toward Reliable Agent Development

Agents can expand the covariate space of randomized experiments by retrieving fast-moving local context missed by slow-changing survey baseline covariates, helping characterize who benefits most from an intervention. Verifying such covariates is difficult: individual treatment effects are unobserved, retrieval leakage can pull post-treatment information into nominally pretreatment summaries, and encoder leakage can inject post-treatment pretraining knowledge into representations even after temporal filtering of inputs. Guided by a two-channel information bound separating summary provenance from encoder weights, we propose a three-layer benchmark protocol: (i) retrieval admissibility via pre-treatment date filtering; (ii) heterogeneity validation scored rank-weighted average treatment effects (RATEs); and (iii) encoder admissibility checked with chronologically vintaged encoders, future-fact probes, and weight perturbations. Across 11 datasets anchored by Uganda's Youth Opportunities Program, we compare session-isolated retrieval (sandboxed, bounded-budget agent runs per study) against a persistent workspace teammate (xAI's GrokBot) that builds one date-verified corpus per study while blinded to outcomes. The workspace teammate yields higher mean RATE ratios in 6/11 datasets for text alone and 7 for combined features, though paired tests show neither workflow universally dominates. Even on fixed retrieved text, encoder choice significantly shifts heterogeneity signal. Chronologically vintaged probes show no clear evidence of weight leakage, but single-record adapter perturbation analyses show that memorized future facts, once present, persist until injected noise degrades model output. Temporal filtering of retrieval is necessary but insufficient: verifying agent-generated covariates requires jointly examining source provenance, out-of-sample treatment-effect signal, and encoder weights.

0.38

Can JEV Support Clinical Trial Criteria Assessment?

cs.LG cs.AIcs.CL ·2026-10-26 ·Mengxian He, Ziyue Gao, Chun Li, Shunyi Zhang, Hao Wei +2 more
hot direction similarity 0.56
Abstract

Clinical trial prescreening requires distinguishing unmet conditions from insufficient evidence in patient records. Given patient records, criterion questions, and predefined answer options, we retrospectively compared JEV, a non-generative decision model returning native option probabilities, with schema-constrained Qwen Flash across 2,048 test patient-condition pairs from TrialGPT and question-answer datasets derived from MIMIC-III and MIMIC-IV, all evaluated under strict Zero Data Retention (ZDR) policies to ensure clinical data privacy. Both models assessed conditions individually or in batches sharing the same patient context, with performance measured against reference labels. In batch mode, JEV and Qwen achieved similar macro-F1 scores on TrialGPT (0.652 vs. 0.660) and MIMIC-IV (0.807 vs. 0.814), whereas JEV substantially outperformed Qwen on MIMIC-III (0.768 vs. 0.534; $Δ$ = +0.234, 95% CI: 0.187-0.281). This advantage largely reflected higher recall for conditions labeled as having insufficient information (56.3% vs. 9.9%). Across all three datasets, JEV also had lower observed median job latency (1.18-1.40 vs. 2.80-8.90 s) and 53%-74% lower estimated cost per condition. These findings position JEV as an initial assessment component that provides criterion-level judgments and flags potential information gaps for review. JEV's observed errors in interpreting clinical evidence underscore the need to verify its outputs against patient records before they inform eligibility decisions.

0.29